FATE
Fate Therapeutics, Inc. (FATE) ESG Analysis Analysis (2026)
Overall Score
Environmental
No material environmental disclosures or sustainability initiatives were provided in the fresh data.
The company remains loss-making with negative operating and free cash flow, limiting near-term ESG investment capacity.
R&D intensity is high at 15.0% of revenue, but there is no evidence in the fresh data that it is tied to a material environmental program.
Social
No material social disclosures, workforce metrics, or community initiatives were provided in the fresh data.
Operating performance remains weak, with negative net margin (-19.4%) and negative ROE (-65.1%), which can constrain employee and stakeholder support.
Stock-based compensation is 2.7% of revenue, but the fresh data does not indicate a meaningful change in social practices.
Governance
No material governance updates, board changes, or compliance events were provided in the fresh data.
Liquidity remains strong with a current ratio of 4.85 and cash per share of 1.28, but profitability and cash generation remain negative.
The company continues to show weak capital efficiency, with negative ROIC (-57.5%) and negative free cash flow yield (-37.3%).
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Fate Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

